Domestic collaborative research of Genome-wide association study (GWAS) in predicting the therapeutic responce and adversed effect of new anticancer drugs for hepatocellular carcinoma.

Domestic collaborative research of Genome-wide association study (GWAS) in predicting the therapeutic responce and adversed effect of new anticancer drugs for hepatocellular carcinoma. - New anticancer drugs for hepatocellular carcinoma and GWAS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008061

Enrollment

300

Registered

2012-07-01

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carinoma

Interventions

New anticancer drugs for the treatment of hepatocellular carcinoma approved after April 2009

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hepatocellular carcinoma who were treated by new anticancer drugs for the treatment of hepatocellular carcinoma approved after April 2009

Exclusion criteria

Exclusion criteria: Patients whom the physicians in charge judge their enrollment inappropriate

Design outcomes

Primary

Measure	Time frame
Relationship between genetic factor and therapeutic response / adversed effect to new anticancer drugs for the treatment of hepatocellular carcinoma	—

Countries

Japan

Contacts

Public ContactShuichi Kaneko

Graduate School of Medical Sciences, Kanazawa University Disease Control and Homeostasis

s-kaneko@m-kanazawa.jp076-265-2000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026